Northwest Biotherapeutics Inc (QB) (NWBO) News

It states dollars on the chart.

Yes, and that "NWBO rep guy / Investment banker guy" does PIPE's.

Also interesting, the day of and the day after clinical trials.gov combination trial masking change was submitted (9/11), the FINRA short volume ratio spiked to 61.34 and 59.89. The change was not posted by clinical trials for eight more days. The Sept13th short interest in shares and dollars will both be interesting.

See the update of the two trials on dendritic cells. One is the combo trial and the other run by Roswell Park.

Would it be fair to say that someone or some government sector is watching this two trials closely?





Recall when LP started negotiation with Roswell Park, was it over two years ago? Guess what? Coincidentally over two years ago, the clinical trial on dendritic cells run by Roswell was switched to the program funded by DoD. But you don't believe coincidence, do you? Did you mock me when I listed all the dendritic cell trials funded by DoD?

Most folks measure short interest in shares. That is why it's misleading and that's why it was misleading for Beartrap.

The chart is not misleading. It is short interest in dollars. As of the last dissemination, it was about as cheap as can be for shorts to completely cover their old positions. Let’s see how much was left of their dollar interest on September 13.

Prior to that, you’d have to go back to the end of 2021 to see such a low short interest in dollars.

They don’t need to . They have been diluting enough every day .

I think they were talking about their theory of financiers motivated to get the price down before financings.

They already said on the BBS that they'd try to crater the stock pre PIPE financing.

>>Our deep dip in price

Tomorrow marks 6 years post AMRN announcement. Will 9-24-24 hold the same fate for NWBO?

That and $DJT are just another grift, imo.

I don’t think the longs are going to sell 50,419,205 shares at .3333333333 or .3333333334. The MM better get out of the 6th decimal position.

Today's OS is 1,276,923,405. The company has been diluting 1 million shares every business day so far in the month of September.

Lots of big lots... 20,000, 50,000, 100,000, 200,000... have been going on this past week or so with little movement in price.

I can understand that. I find the cost on the annual subscription to be worth in reduced aggravation since I can see 50 posts on one page and don't have to deal with the ads. There is the index of posts page so you can see all the posts and the emoji ratings as a single line entry per post. Also being able to use the search function is helpful even if it is pretty rudimentary. The ability to PM is an added bonus.

I guess I'm fortunate that I can afford the indulgence.

Thanks, brooktrail. Shares vs. dollars. Our deep dip in price is part of the decline we see in short interest.

The short interest is generally declining. Next short dissemination date is tomorrow (9/24/2024) at 4 pm eastern time. That will get people current to 9/13. We will see if the trend continued.

Earlier today over 600,000 shares in two trades(283,000, 349,000?), one right after the other, about 10:30 raised the price only .002, if I remember correctly. Is that MMs somehow mysteriously holding the price down for short covering?
Lots of big lots... 20,000, 50,000, 100,000, 200,000... have been going on this past week or so with little movement in price. I know a few other posters have pointed it out.
Any thoughts?

The chart is misleading. It's in dollars, not shares. Adjusted for the current price, there are still around 50 million shares short. Adjusted for price, last year's share short total is not much different than current.

Short Interest
Date Short Interest % Change AVG. Daily Share Vol Days to Cover Split New Issue
08/30/2024 50,419,205 0.33 5,798,199 8.7 No No

Interesting, Flipper. It looks to me like short interest was 50 mill on August 30 over on the otcmarkets.com. Are the shorts finally covering? Are they really down to 16 mil?

that's funny. you made me laugh.. It's been a long road for some of us... You got to keep your sense of humor

Turner5 Just what this board needs right now, another friggin gypsy palm reader. What's next telling us to hang garlic and wolf baine in our houses??.

Look closely.

You’re not alone in not wanting to upgrade at the high cost. I’m in the same boat as are many others!

I’ve read more than enough of the FUDsters negative narratives.

So much so that I put a handful on ignore, first ignores in all the years of reading this board.

I don't think you can extract too much info from the volume. Did you take a big dive into when and how Baker Brothers dealt with their portfolio in target therapy?

The fee for ihub is too expensive and I cannot afford. I think this could be the reason that over the past two years the number of followers on this board remains unchanged. LoL.

That's why I cannot send a private message to the longs to exchange the thoughts on this one.

Ask your boss.

Now that would be transformative. The Market Makers would get eaten alive.

Wow, this site has become very 'glitchy'. Bills paid up?

The wonderful season of fall has begun ;)

You haven't read what exwannabe posts or the bashers ?

only those who hold shares will be millionaires; the shorts on the other hand will be paupers.

MAA STATUS: June 29, 2024 Flashback (see quote below).

(Note: At this point, some longs are now thinking 210 window started March 7 and Goes to October 3, although everyone (longs and bears) recognizes regulatory speed is variable but improving this year. In other words, MHRA could take a little longer.

August 2 (8k) seemed to indicate inspections were planned during the last 70 day window.

On September 10, Advent received Human MIA for commercial manufacturing. This seemed to complete one of the major hurdles.)


Linda Powers, June 29, 2024

“So, needless to say, our top priority, our laser focus, is to complete the process, and hopefully obtain our first commercial approval in the UK, hopefully, approval of the MAA.

We are well underway. We believe the MHRA is following the 150-day process that they have, but we don’t, we do not have confirmation of that. We don't have a way to be sure of that, to know it for sure, but we believe that. It, the “150 days,” quote, unquote, involves approximately 3 stages, and the time frame of each stage is approximate. So it's not, you know, on the button.

The first stage is approximately 80 days of initial review of the application. The second stage is approximately 60-day clock stop, when the agency is going to deliver a list of questions to us, as they do in all these processes. It's not just us. They'll deliver a list of questions. They'll ask for supplementary information, all of that. And, and we will try to respond as fast as we can, which is part of why we're trying to guess what they might might ask, and try to already kind of prepare.

The 3rd stage, which will come after the 60-day clock stop, or however long the clock stop turns out to be, to provide all the answers and info, additional information. The third stage is approximately 70 days of further review, and reaching a decision. Again, the the timelines are approximate. As as far as we've seen, there is not an equivalent thing in the UK that's similar to a PDUFA date in the US. You know, under the legislation in the US, you know, FDA can have a target date for giving you a decision.

We don't have a target date. It'll be what it'll be, okay? And those approximate time frames of those 3 stages that I described, of course, depend also on MHRA's workload, and what backlog they have, and so forth. So that's the approximate process, and the approximate timelines.

I mentioned, with a lot of emphasis, and a lot of discussion about the inspections, that they're gonna inspect everyone, and everything. Those are gonna be going on all during this MAA review process, and those will have to be completed before an MAA decision can be rendered. Right? So there's gonna be extensive inspections, and it's gonna be going on, during this period.

So we, the typical thing, we are gonna follow the typical practice of biotech and pharma companies, which is, we are not going to provide interim step blow by blow. They asked us this, we answered that. They asked us the next thing, we answer that. No, we’re not gonna do the interim steps. We're just going to tell the result when the process is finished. That's the typical approach, and that's the approach that we're gonna be taking. Okay. That's our big priority area, of course.” — Linda Powers

What age are you living? Stone age?

What's the occurrence rate of psudoprogression in the p3 trial? We are living in an age that things can be analyzed on molecular and genetic level. Have you seen the variation of mutated genes before and after DCVax-L treatment? Have you seen the t-cell expansion after DCVax-L treatment? You do know that DCVax-L can present hundreds of tumor-associated antigens to immune cells, don't you? Yet you still spread nonsense that there are so many dendritic cell vaccines trying to make frivolous the biggest breakthrough.

The approval will not come from MHRA only. The approval will not be about DCVax-L only. DCVax-L will be assigned Platform Technology Designation by FDA.

Gary,

DCVAX-L not only can treat solid tumors or most diseases treatable by immunotherapy but can also work as a platform for the development of drugs (precision medicine) and vaccines. IMO, the latter can bring immediate value to the company since BPs have to sign the deal and front the money.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175122476

When we speak about future valuations, if we don't include assumptions about what the estimate is based on it's practically meaningless. It's my belief that both DCVax's have the potential of treating many solid cancers, it will take many years, perhaps over a decade to verify this. If verified and approved for use worldwide, then I think discussions of trillion dollar market caps are warranted. That's the extreme high valuation.

On the other hand, approval for brain cancers only, but ultimately worldwide. That could take as many as perhaps 5 years, but at that point mid double digit billion dollar market caps should certainly be reasonable to expect.

I believe we'll be somewhere in the middle, substantial anecdotal evidence of efficacy in other cancers resulting in substantial off label use in the next 5 years. If I'm right about that, in that time we could see low triple digit billion market caps.

Regulatory approvals certainly take time, they cost money, while I believe that there is a possibility some countries may piggy back on the UK approval, nothing is certain until it occurs.

Gary

Yep huge reversal . We are all millionaires now

Wow u still care about shareholders from 20-30 years ago ..

More FUDSTER BS ..

just admit someone pays u to have a negative opinion and post under multiple aliases 30-50x a day making all kinds of false negative claims and opinions

That u have been here over 10 years and 10k posts just under the LC alias …

We don’t know all your multiple personalities on this board but u likely have 20-30k FUDSTER posts

What a sad person u must be

Btw, at the very end of the Tempest Therapeutics BBS interview the CEO (yes, that's right the CEO) says no compassionate use when going for Plll FDA approval.

Ugh...Had to watch it again.

08/26/24- Big Biz Show- Howie Font, Gold Royalty Corp., My Patriot Supply, & Mike Taylor

"They're trying to get the FDA to approve what they're doing"

BBS guy 38:07

BBS guy talking about "Whacking that thing" to get the PIPE at the cheapest price possible. Lots of nervous laughter.

42:00.

Kinda like the bank robber returning the loot.

Looks like they are going to Reverse the direction of their spoofing, LoL.

308k bid. something brewing?

Learning curve, sorry I was busy this morning. Frozen tissue plays an important role in creating DCVax-L. See extract from Google search

DCVax-L and Frozen Tumors
DCVax-L is a personalized immunotherapy treatment that utilizes a patient's own immune system to fight cancer. It's particularly promising for patients with glioblastoma, a highly aggressive form of brain cancer.
Frozen tumor tissue plays a crucial role in the creation of DCVax-L. Here's how:
* Tissue Extraction: During surgery, a portion of the tumor is removed and immediately frozen.
* Cell Isolation: The frozen tissue is then thawed, and specific immune cells are isolated.
* Vaccine Creation: These cells are cultivated and engineered to recognize and attack the patient's unique tumor cells.
* Administration: The resulting vaccine is administered to the patient in a series of injections.
Key Points to Remember:
* Freezing: The tumor tissue needs to be frozen immediately to preserve its properties for vaccine production.
* Preservation: The tissue should be stored without preservatives or chemicals that might interfere with the process.
* Gliadel Wafers: If Gliadel wafers (chemotherapy-soaked wafers) were used during surgery, they can interfere with DCVax-L's effectiveness.
If you or someone you know is considering DCVax-L treatment, it's essential to discuss the specific requirements with a healthcare professional. They can determine if you're eligible and provide guidance on the process.
Would you like to know more about DCVax-L, glioblastoma, or immunotherapy in general?

Thus, for months facilities & PATIENTS from AROUND THE GLOBE have been freezing their tumors. I would bet these frozen pieces have been transported to the UK. When they change the designation to HUMAN what would stop them from fabricating the Vaccine? Understanding of course they cannot distribute until approval. I’m sure, in some cases, they will begin the fabrication process.

Do they still report the numbers of people under treatment in their [NVCR] quarterlies? Has it grown, or is it still around 3,500(?) ?
It had grown to 4000 in Q2 with France coming online.

If you really care, NVCR is never going to be more than a "meh" player in the field with just GBM. So that indication does not justify the market cap. There current revenue is $150M/q and they might possibly grow it to $250 with only GBM. But that would only justify a $3-4B market cap.

They need the larger indications (NSCLC, pancreatic and whatever) to come in. They plan to commercially launch lung in US and Germany this year, but despite being a larger market there are legit doubts based on the failure post 1st line CI. They do have more trials that can matter. The combo trials with CIs in front line NSCLC and GBM, along with the PANOVA trial in pancreatic are the main ones, though some of the smaller efforts can help.

I find the idea that it is NVCR vs NWBO somewhat humorous. Both companies have to deal with their own issues, and both will succeed or fail on their own.

Immense upside. We only need to let the regulatory process play out as it has consistently in favor of DCVax approval.

Crash is 0-50, a perfect losing prediction rate.

You mean like my bets on significant revenue in past years and approval by 2023 summer , 2024 august? I must have missed the news on those.

There is exactly one where I was surprised and admit being wrong. I did think they would not get into a JAMA level journal w/o significantly cleaning up the article. They did clean it up some (admitting to the efficacy IA and trial limitations), but I did expect more was needed.

How about some more important ones. That the trial had failed PFS. That the trial had failed OS with the randomized arm. That there really had been an efficacy IA in 2015 (which creates serious issues for endpoint change).

Feel free to actually go against me with some forward bets.

How about no MHRA MAA approval this year? No terms needed, just a friendly bet. Come on, step to the table.